Insider buying last 90 days
No open-market insider purchases were filed for RMD in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every RMD insider filing, plotted on the chart in Gekko.Open RMD in Gekko
NYSE: RMD
ResMed (RMD) Stock Analysis & Forecast
$224.99−3.43 (−1.5%)
Close on Sep 18, 2026. Page updated Sep 19, 9:19 pm ET.
Gekko Brief
AI summaryResMed (RMD) closes at $224.99, down 1.5%, sitting between its 50-day average of $218.41 and 200-day average of $227.20. The GekkoIndex reading is 57.1, placing the stock in the Neutral zone. Price stands 20.8% below Gekko Fair Value of $284.00, a notable gap over the past year in which shares are down 17.2%, though up 19.3% over three months.
This week's news centers on an analyst upgrade and fresh institutional positioning. RBC Capital Markets raised its rating to Outperform from Sector Perform and lifted its price target to $262.00 from $244.00, citing sleep apnea device sales growth, particularly international volumes; shares rose 3.05% on 15 September following the move. Separately, Bank of America Corp DE disclosed a new stake of 775,424 shares valued at approximately $151.1 million, and Nykredit A/S purchased 338,702 shares valued at approximately $66 million, both second-quarter filings; Engineers Gate Manager LP raised its stake by 77.8% in the same period. Coverage also notes ResMed's position in the obstructive sleep apnea treatment market amid competitive pressure.
Over the next 20 trading days, the next earnings date falls on 29 October, 39 days out and beyond a typical holding window. Analyst coverage stands at 15 firms, with 5 buy and 10 hold ratings and a consensus target of $246.44, implying 9.5% upside from current levels. Seasonality over 5 years shows an average 20-day return of -3.3% from this point in the calendar, positive in only 1 of those years, a factor worth noting alongside the current fair-value gap.
Written by AI and checked automatically against the figures on this page. Generated Sep 20, 2026 from the data above.
Price vs fair value
Close $224.99200-day averageGekko Fair Value $284.00
Key stats
- Market cap
- $32.64B
- P/E ratio
- 21.9
- Forward P/E
- 19
- EPS, TTM
- $10.44
- Revenue, TTM
- $5.65B
- Profit margin
- 27%
- Dividend yield
- 1.05%
- Beta
- 0.77
- Volume
- 3.82M avg 1.34M
- 1-year return
- −17.2%
- Typical daily move
- ±2.8%
- Typical 20-day move
- ±4.9%
- 50-day average
- $218.41
- 200-day average
- $227.20
- Next earnings
- Oct 29 after close
- Shares outstanding
- 144.3M
ResMed swing-trade checklist
ResMed scores 2 supportive, 2 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive2 mixed1 headwind
- Trendmixed
Averages disagree
Close $224.99 sits between the 50-day ($218.41) and 200-day ($227.20) averages, or the averages disagree.
See the chart - GekkoIndexmixed
57.1, Neutral
Reading 57.1 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
20.8% below
Price is 20.8% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 39 days
Next report Oct 29, 2026, 39 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−3.3% on average
From this point in the calendar, the next 20 trading days averaged −3.3% over 5 years, rising in 1 of them.
See seasonality
A description of current data, not a recommendation. How this page works
ResMed stock chart and price history
ResMed closed at $224.99 on Sep 18, 2026, −17.2% over the past year, inside a 52-week range of $180.27 to $284.87.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −2.5%
- 3 months
- +19.3%
- 6 months
- −1.1%
- 1 year
- −17.2%
The full RMD chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open RMD in Gekko
Follow ResMed through every session
Put RMD on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track RMD in GekkoFree for 7 days. No credit card required.
About ResMed
ResMed designs, builds and sells medical devices and connected digital tools aimed at people with respiratory conditions, particularly sleep apnea. Its equipment lineup spans ventilators, diagnostic machines, masks and headgear for both clinical and home use, along with dental devices. The company is also known for pairing this hardware with software that helps clinicians and patients track therapy and manage care remotely.
The business is organized into two segments, one covering sleep and respiratory care hardware and the other focused on software delivered as a service. On the software side, tools such as AirView let providers monitor devices remotely, myAir helps patients stay engaged with their own therapy, and U-Sleep tracks compliance for home medical equipment suppliers. ResMed also runs platforms like Brightree, MatrixCare and HEALTHCAREfirst, which support home care providers, senior living and hospice organizations, and home health agencies with business management, care coordination and records. Its customers include sleep clinics, home healthcare dealers and hospitals, reached through a direct sales force and distributors across roughly 140 countries.
ResMed was founded in 1989 and is headquartered in San Diego, California. Its shares are listed on the NYSE under the ticker RMD.
- Listed
- NYSE
- Sector
- Health technology
- Industry
- Medical specialties
- Website
- resmed.com
ResMed GekkoIndex: the smart money zone
ResMed’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 57.1, in the Neutral zone, down 5.3 points over five sessions.
57.1Neutral
Down 5.3 points over five sessions, from the Accumulation zone.
Reading for Sep 18, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 40 | +1.0% | +3.1% | ||
| Accumulation | 218 | +0.8% | +1.4% | ||
| Neutral (current zone) | 366 | 0.0% | +0.7% | ||
| Distribution | 32 | −1.7% | −2.8% | ||
| Selling | 6 | Too few readings yet | |||
Average RMD share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.2% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the RMD price, zone by zone.Track RMD in Gekko
Is ResMed stock overvalued? Gekko Fair Value
ResMed trades 20.8% below Gekko Fair Value of $284.00, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what ResMed shares are worth, recalculated every trading day.
$284.00
Gekko Fair Value, Sep 19, 2026
20.8% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open RMD in Gekko
ResMed insider and Congress trading
No open-market insider purchases were filed for ResMed, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in RMD were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for RMD, plotted on the chart in Gekko.Open RMD in Gekko
Buybacks
ResMed has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $700.0M
- As a share of market cap
- 2.14%
- Trailing four quarters
- $1.20B
From company filings.
Hedge funds and billionaires quarter ended Dec 31
0of the funds Gekko tracks hold RMD.
0added0opened0trimmed2sold out
Which funds are on each side, name by name.Unlock in Gekko
ResMed earnings: next date and track record
ResMed reports on Oct 29, 2026, after the close (39 days away), and beat the EPS estimate in 6 of its last 8 reports.
Next earnings report
Oct 29, 2026
Expected after the close, 39 days away
- EPS estimate
- $2.69
- Revenue estimate
- $1.39B
6 of 8reports beat the EPS estimate
±4.6%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 6, 2026 AI summary
- What they said
- ResMed reported a strong Q4 FY2026 and full-year performance, driven by device and mask volume growth, supply-chain productivity gains, and margin expansion. Q4 revenue was $1.5 billion (9% headline, 8% constant-currency) and non-GAAP EPS grew 16% to $2.95. FY2026 finished with 10% headline revenue growth, 180 bps operating margin expansion, and more than $1.6 billion in free cash flow; management returned over $1 billion to shareholders (share repurchases and dividends). Leadership emphasized continued operational and innovation excellence, active portfolio management (including tuck‑in M&A in the $100–$500M range), disciplined capital allocation, and increasing investment in R&D, marketing, and AI-enabled productivity. Management introduced additional revenue disclosure splitting device revenue into sleep and life‑support categories, and provided annual guidance for FY2027. Key negatives discussed were inflationary pressures (electronic components, freight), a material Astral field action (a $42M Q4 accrual and a ~$75M FY2027 top-line headwind, ~ $0.15 EPS impact), and modest near‑term gross margin pressure (Q‑over‑Q decline of ~50 bps). Management reiterated a patient‑first, conservative recall approach and embedded the Astral headwind in FY2027 guidance. The tone was confident and measured: management acknowledged headwinds but emphasized growth via volume, ongoing demand generation, productivity improvements, and strategic M&A.
- Guidance
- FY2027 revenue growth guidance: +5% to +7% (includes Astral headwind). FY2027 core non-GAAP EPS guidance: +12% to +14% (core), which embeds the Astral impact (Astral ~ $75M top-line headwind and ~ $0.15 EPS headwind). Management also guided to low-double-digit gross margin improvement for the year and slight operating margin expansion.
- Risks flagged
- Astral field action/recall (Q4 accrual ~$42M; FY2027 ~$75M headwind), inflationary pressures (electronic components, freight), FX headwinds (noted ~20 bps Q‑over‑Q), regulatory and product quality/recall risk, reimbursement/capitated reimbursement environment, and competitive dynamics in global markets.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | $2.95 est $2.90 | $1.46B est $1.46B | −5.4% |
| Apr 30, 2026 | $2.86 est $2.78 | $1.43B est $1.42B | −3.3% |
| Jan 29, 2026 | $2.81 est $2.72 | $1.42B est $1.40B | +0.2% |
| Oct 30, 2025 | $2.55 est $2.51 | $1.34B est $1.33B | −2.7% |
| Jul 31, 2025 | $2.55 est $2.55 | $1.35B est $1.35B | +0.6% |
| Apr 23, 2025 | $2.37 est $2.38 | $1.29B est $1.29B | +10.3% |
| Jan 30, 2025 | $2.43 est $2.31 | $1.28B est $1.27B | −6.6% |
| Oct 24, 2024 | $2.20 est $2.04 | $1.22B est $1.19B | +7.9% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
ResMed stock forecast and analyst price targets
Analysts’ average 12-month price target for ResMed is $246.44, +9.5% from the last close, from 15 firms rating the stock in the last 90 days.
$246.44consensus 12-month target, +9.5% from the last close
Now $224.99Avg $246.44
Low $213High $320
Each firm’s latest rating in the last 90 days: 15 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 15 | RBC Capital | $262 | +16.4% |
| Sep 10 | Citi | $240 | +6.7% |
| Aug 31 | KeyBanc | $267 | +18.7% |
| Aug 19 | Rothschild & Co Redburn | $230 | +2.2% |
| Aug 11 | Mizuho Securities | $235 | +4.4% |
+0.7%average 20-day move after past Neutral readings
−3.3%average move over the next 20 trading days in the last 5 years
±2.8%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
ResMed seasonality: the next 20 trading days
Over the next 20 trading days from Sep 19, ResMed averaged −3.3% across the last 5 years, rising in 1 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −1.8% | 1 of 5 |
| Next 10 trading days | −1.5% | 3 of 5 |
| Next 15 trading days | −2.0% | 1 of 5 |
| Next 20 trading days | −3.3% | 1 of 5 |
| Next 30 trading days | −3.3% | 1 of 5 |
For scale, RMD’s typical 20-trading-day move in either direction is about 4.9%.
ResMed market cap and key statistics
ResMed’s market cap is $32.64B, with a P/E ratio of 21.9 and revenue of $5.65B over the last twelve months.
Valuation
- Market cap
- $32.64B
- P/E ratio
- 21.9
- Forward P/E
- 19
- EPS, TTM
- $10.44
- Gekko Fair Value
- $284.00
Trading
- Volume
- 3.82M
- Avg volume, 20 days
- 1.34M
- 52-week high
- $284.87
- 52-week low
- $180.27
- Shares outstanding
- 144.3M
Financials
- Revenue, TTM
- $5.65B
- Profit margin
- 27%
- Return on equity
- 24.3%
- Quarterly earnings growth, YoY
- +2.4%
Risk and income
- Beta
- 0.77
- Typical daily move
- ±2.8%
- Typical 20-day move
- ±4.9%
- Dividend yield
- 1.05%
ResMed stock news this week
Coverage of ResMed this week reads positive: 11 positive, 5 neutral and 2 negative headlines.
- ResMed Inc. (RMD)’s Sleep Apnea Leadership Supports Growth Despite Rising Competitive PressuresInsider Monkey, Sep 19
- Nykredit A S Makes New Investment in ResMed Inc. $RMDMarketBeat, Sep 19
- Resmed Inc. : RBC Raises to Outperform From SMoomoo, Sep 18
- Bank of America Corp DE Buys New Stake in ResMed Inc. $RMDMarketBeat, Sep 18
- Engineers Gate Manager LP Has $1.58 Million Stake in ResMed Inc. $RMDDefense World, Sep 17
- ResMed Shares Jump Following RBC Capital Upgrade to OutperformTIKR.com, Sep 16
ResMed peers
ResMed’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Distribution | 17.1% above |
| ABTAbbott Laboratories | Accumulation | 15.5% below |
| DHRDanaher | Neutral | 1.1% above |
| ISRGIntuitive Surgical | Neutral | 12.3% above |
| MDTMedtronic | Neutral | 24.7% below |
| SYKStryker | Buying | 17.1% below |
A peer links to its own page where one exists.
ResMed stock FAQ
What is ResMed’s market cap?
ResMed’s market cap is $32.64B at the Sep 18, 2026 close of $224.99, with 144.3M shares outstanding. The shares trade on a P/E ratio of 21.9.
What is the ResMed stock forecast?
The consensus analyst 12-month price target for ResMed is $246.44, +9.5% from the last close. Of the 15 firms that rated the stock in the last 90 days, 5 rate it a buy, 10 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is ResMed stock overvalued or undervalued?
On Gekko’s estimate ResMed is undervalued: the Sep 18, 2026 close of $224.99 is 20.8% below Gekko Fair Value of $284.00. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does ResMed report earnings next?
ResMed is expected to report on Oct 29, 2026, after the market closes (39 days away). Analysts expect earnings of $2.69 per share on revenue of $1.39B. ResMed beat the earnings estimate in 6 of its last 8 reports, moving 4.6% on average across the report.
What is ResMed’s 52-week high and low?
ResMed’s 52-week high is $284.87 and its 52-week low is $180.27; it closed at $224.99 on Sep 18, 2026, −17.2% over the past year.
Is ResMed stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (fair value and earnings risk), 2 as mixed (trend and gekkoindex) and 1 as a headwind (seasonality). The checklist is a description of current data, not a recommendation.
How this page works
Prices and signals update after every US market close; the GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See ResMed the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,349 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.